ADMA Biologics Investigated for Securities Fraud After Stock Drop

BFA Law probing claims of channel stuffing and undisclosed related party distributor after 29% plunge

Mar. 31, 2026 at 11:20am

Got story updates? Submit your updates here. ›

A high-contrast black and white close-up image of the inner workings of a financial mechanism, such as gears or circuits, conveying a sense of the intricate systems that power the biotech industry.An investigation into alleged financial irregularities at ADMA Biologics exposes the complex machinery underlying the biotech industry.NYC Today

Leading securities law firm BFA Law is investigating ADMA Biologics after the company's stock price plummeted 29% due to allegations from research firm Culper Research of channel stuffing and the use of an undisclosed related party distributor, potentially violating federal securities laws.

Why it matters

The allegations against ADMA Biologics, if proven true, could have significant legal and financial implications for the company, including potential fines, lawsuits, and damage to its reputation. This case highlights the importance of transparency and accurate financial reporting for publicly traded companies.

The details

According to the Culper Research report, ADMA Biologics allegedly engaged in channel stuffing, a practice where a company artificially inflates sales by sending more products to distributors than they can reasonably sell. The report also claims ADMA used an undisclosed related party distributor, which could violate regulations around related party transactions.

  • ADMA Biologics' stock price dropped 29% on March 31, 2026 following the release of the Culper Research report.

The players

ADMA Biologics Inc

A biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases.

Culper Research

An independent research firm that publishes reports on publicly traded companies, often highlighting potential issues or concerns.

BFA Law

A leading securities law firm that is investigating the allegations against ADMA Biologics.

Got photos? Submit your photos here. ›

What’s next

BFA Law will continue its investigation into the allegations against ADMA Biologics to determine if the company violated any federal securities laws.

The takeaway

This case highlights the importance of transparency and accurate financial reporting for publicly traded companies, as allegations of misconduct can have significant legal and financial consequences.